NIAMS Multidiciplinary Clinical Research Center in Cinc*

总体方案描述：(摘自申请表)本方案 来自辛辛那提儿童医院医疗中心的目标是 影响临床实践，因为它适用于最常见的风湿病 儿童时期的疾病。这一提议也在一定程度上代表了竞争对手 续订中心现有的P60 MAMDC，并免费赠送P30 辛辛那提风湿病核心中心今年早些时候提交的。它是 据估计，美国境内有14万至20万儿童患有风湿病 疾病，许多，但不是全部，都是自身免疫性的。主要的疾病是 幼年类风湿性关节炎、系统性红斑狼疮、硬皮病和 幼年性皮肌炎。影响越来越大的是地区性疾病和 泛发性肌肉骨骼疼痛综合征，其中纤维肌痛是 尤其常见，似乎在频率上增加，可以呈现一种 主要的管理问题。该中心的五个组成部分是：方法核心 与所有项目相互作用；依那西普在青少年中的试验 皮肌炎；青少年发病的心理状态研究 纤维肌痛；使用定量T2标测JRA的影像研究；甲氨蝶呤 JRA的药物基因组学。此外，还有一个行政单位，它 将对所有 通过一个执行委员会、两个咨询委员会和一个 以社区为基础的董事会。短期和长期目标是 改善患有这些疾病的儿童的健康，并更好地确保 从童年和青春期到青年时期的平稳过渡 患有慢性风湿病的孩子。

DESCRIPTION OF THE OVERALL PROGRAM: (Taken from the application) This proposal from the Children's Hospital Medical Center in Cincinnati has the goal of impacting a clinical practice as it is applied to the most common rheumatic diseases of childhood. This proposal also represents in part the competing renewal for the Centers existing P60 MAMDC and is complimentary to the P30 Cincinnati Rheumatic Diseases Core Center submitted earlier this year. It is estimated that 140,000-200,000 children within the United States have rheumatic disease, many, but not all, of which are autoimmune. The major diseases are juvenile rheumatoid arthritis, systemic lupus erythematosus, scleroderma and juvenile dermatomyositis. Of increasing impact are illnesses with regional and generalized musculoskeletal pain syndromes of which fibromyalgia is particularly common and appears to be increasing in frequency and can present a major management problem. The five components of the Center are: A methods core interacting with all projects; A trial of etanercept in juvenile dermatomyositis; A study of psychological status in juvenile onset fibromyalgia; An imaging study using quantitative T2 mapping JRA; Methotrexate pharmacogenomics in JRA. In addition, there is an administrative unit which will exercise operational control and administrative oversight of all the projects through an executive committee, two Advisory Boards and a Community-Based Board of Directors. The short- and long-term goals are to improve the health of children with these conditions and to better ensure a smooth transition from childhood and adolescence through to young adulthood for the child with a chronic rheumatic disease.